Adamas Pharmaceuticals (ADMS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharmaceuticals (NASDAQ: ADMS) reported Q2 EPS of ($0.78), $0.06 worse than the analyst estimate of ($0.72).
For earnings history and earnings-related data on Adamas Pharmaceuticals (ADMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- Ero Copper Corp. (ERO) Tops Q3 EPS by 14c
- i-80 Gold Corp. (IAUX) Misses Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
